FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992624894> ?p ?o ?g. }

• W1992624894 endingPage "1633" @default.
• W1992624894 startingPage "1625" @default.
• W1992624894 abstract "The main objective of the current post hoc analysis was to compare patient-reported outcomes between crizotinib (N = 172) and chemotherapy subgroups (pemetrexed [N = 99] and docetaxel [N = 72]) in previously treated patients with advanced ALK-positive non-small-cell lung cancer, in PROFILE 1007 study (Pfizer; NCT0093283).Patient-reported outcomes were assessed at baseline, day 1 of each cycle, and end of treatment. General health status was measured using the EuroQol-5D visual analog scale and health utility index scores were assessed using the EuroQol-5D descriptive system. Functioning, lung cancer symptoms, and global quality of life (QOL) were assessed using European Organisation for Research and Treatment of Cancer QLQ-C30 and the QLQ-LC13 lung cancer module. Repeated measures mixed-effects analyses compared overall scores and change from baseline scores, controlling for baseline scores.The overall mean EQ-5D health utility index scores (95% CI) on treatment were significantly greater (p < 0.05) for crizotinib (0.82 [0.79-0.85]) than for chemotherapy (0.73 [0.70-0.77]; 0.74 [0.70-0.79] for pemetrexed and 0.66 [0.58-0.74] for docetaxel). A significantly greater improvement from baseline was observed with crizotinib versus pemetrexed and versus docetaxel treatment groups for general health status, physical functioning, global QOL, dyspnea, fatigue, and pain. Improvement rates for fatigue, cough, pain, dyspnea, and global QOL were significantly greater on crizotinib compared with pemetrexed and docetaxel, respectively. Worsening rates for diarrhea and constipation were higher with crizotinib.The benefits of crizotinib in improving symptoms and QOL are demonstrated regardless of whether the comparator is pemetrexed or docetaxel." @default.
• W1992624894 created "2016-06-24" @default.
• W1992624894 creator A5005127397 @default.
• W1992624894 creator A5019037704 @default.
• W1992624894 creator A5020327537 @default.
• W1992624894 creator A5023794502 @default.
• W1992624894 creator A5029270472 @default.
• W1992624894 creator A5043397424 @default.
• W1992624894 creator A5045713635 @default.
• W1992624894 creator A5061648315 @default.
• W1992624894 creator A5080311196 @default.
• W1992624894 creator A5089954905 @default.
• W1992624894 date "2014-11-01" @default.
• W1992624894 modified "2023-10-12" @default.
• W1992624894 title "Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non–Small-Cell Lung Cancer" @default.
• W1992624894 cites W1947168884 @default.
• W1992624894 cites W1968765750 @default.
• W1992624894 cites W1970299210 @default.
• W1992624894 cites W1992245683 @default.
• W1992624894 cites W2007606124 @default.
• W1992624894 cites W2037177568 @default.
• W1992624894 cites W2050249255 @default.
• W1992624894 cites W2068811106 @default.
• W1992624894 cites W2071539936 @default.
• W1992624894 cites W2087190171 @default.
• W1992624894 cites W2101379915 @default.
• W1992624894 cites W2109567704 @default.
• W1992624894 cites W2115012618 @default.
• W1992624894 cites W2125760261 @default.
• W1992624894 cites W2130488043 @default.
• W1992624894 cites W2134667653 @default.
• W1992624894 cites W2137586470 @default.
• W1992624894 cites W2159866564 @default.
• W1992624894 cites W2166084034 @default.
• W1992624894 cites W2167571044 @default.
• W1992624894 cites W2168323778 @default.
• W1992624894 cites W2169331014 @default.
• W1992624894 cites W2330814896 @default.
• W1992624894 cites W81256119 @default.
• W1992624894 doi "https://doi.org/10.1097/jto.0000000000000318" @default.
• W1992624894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25436797" @default.
• W1992624894 hasPublicationYear "2014" @default.
• W1992624894 type Work @default.
• W1992624894 sameAs 1992624894 @default.
• W1992624894 citedByCount "69" @default.
• W1992624894 countsByYear W19926248942015 @default.
• W1992624894 countsByYear W19926248942016 @default.
• W1992624894 countsByYear W19926248942017 @default.
• W1992624894 countsByYear W19926248942018 @default.
• W1992624894 countsByYear W19926248942019 @default.
• W1992624894 countsByYear W19926248942020 @default.
• W1992624894 countsByYear W19926248942021 @default.
• W1992624894 countsByYear W19926248942022 @default.
• W1992624894 countsByYear W19926248942023 @default.
• W1992624894 crossrefType "journal-article" @default.
• W1992624894 hasAuthorship W1992624894A5005127397 @default.
• W1992624894 hasAuthorship W1992624894A5019037704 @default.
• W1992624894 hasAuthorship W1992624894A5020327537 @default.
• W1992624894 hasAuthorship W1992624894A5023794502 @default.
• W1992624894 hasAuthorship W1992624894A5029270472 @default.
• W1992624894 hasAuthorship W1992624894A5043397424 @default.
• W1992624894 hasAuthorship W1992624894A5045713635 @default.
• W1992624894 hasAuthorship W1992624894A5061648315 @default.
• W1992624894 hasAuthorship W1992624894A5080311196 @default.
• W1992624894 hasAuthorship W1992624894A5089954905 @default.
• W1992624894 hasBestOaLocation W19926248941 @default.
• W1992624894 hasConcept C126322002 @default.
• W1992624894 hasConcept C14184104 @default.
• W1992624894 hasConcept C143998085 @default.
• W1992624894 hasConcept C159110408 @default.
• W1992624894 hasConcept C1862650 @default.
• W1992624894 hasConcept C2776232967 @default.
• W1992624894 hasConcept C2776256026 @default.
• W1992624894 hasConcept C2776694085 @default.
• W1992624894 hasConcept C2776907518 @default.
• W1992624894 hasConcept C2777240266 @default.
• W1992624894 hasConcept C2778239845 @default.
• W1992624894 hasConcept C2778347629 @default.
• W1992624894 hasConcept C2779422266 @default.
• W1992624894 hasConcept C2779951463 @default.
• W1992624894 hasConcept C2781190966 @default.
• W1992624894 hasConcept C71924100 @default.
• W1992624894 hasConceptScore W1992624894C126322002 @default.
• W1992624894 hasConceptScore W1992624894C14184104 @default.
• W1992624894 hasConceptScore W1992624894C143998085 @default.
• W1992624894 hasConceptScore W1992624894C159110408 @default.
• W1992624894 hasConceptScore W1992624894C1862650 @default.
• W1992624894 hasConceptScore W1992624894C2776232967 @default.
• W1992624894 hasConceptScore W1992624894C2776256026 @default.
• W1992624894 hasConceptScore W1992624894C2776694085 @default.
• W1992624894 hasConceptScore W1992624894C2776907518 @default.
• W1992624894 hasConceptScore W1992624894C2777240266 @default.
• W1992624894 hasConceptScore W1992624894C2778239845 @default.
• W1992624894 hasConceptScore W1992624894C2778347629 @default.
• W1992624894 hasConceptScore W1992624894C2779422266 @default.
• W1992624894 hasConceptScore W1992624894C2779951463 @default.
• W1992624894 hasConceptScore W1992624894C2781190966 @default.
• W1992624894 hasConceptScore W1992624894C71924100 @default.

• next